Look at Infosys, Aurobindo Pharma: CK Narayan

CK Narayan, MD of Growth Avenues told CNBC-TV18, "Since earnings season is about to flow the picks would have to be on a slightly dynamic basis because the market will respond more to whatever are the number that will get declared. So, maybe hazarding a guess in advance might be slightly fought with a bit of a risk. So, I would first off suggest that viewers should be pretty nimble about what can be the prospects of stock in the week ahead.""Let us look at some of the leader stocks. Infosys comes to the mind straight off. That is usually the one which triggers off the whole of the earnings season. The way it has moved back again to somewhere near the Rs 1,160-1,180 zone that is clearly the breakout point for the stock to push through. So, my take would be that if the results numbers are able to produce an upside move in Infosys past about Rs 1,175-1,180 levels on the futures that would qualify as a decent buy trigger and this can have a kind of rub off effect on the other IT stocks as well because they have been on an upswing but over the last week they have taken a bit of a breather and are probably waiting for some leader stocks to come out with their numbers. Tata Consultancy Services (TCS) would be the other one. The market doesn't seem to be expecting too much from the leaders. So, there is room for the market to get surprised as far as the IT numbers are concerned.""Next up would of course be the pharma pack which again has been leading the market from front and within this there was a decent pull back in Aurobindo Pharma which has got reversed into yesterday and I would think that Aurobindo Pharma at the current price of about Rs 785 or thereabouts would actually present us with a good opportunity to continue higher. Typically Aurobindo results come in a little later. So, there would be enough room if the market were to pick up some amount of traction particularly in the pharma sector then Aurobindo would be one of the stocks that I would most definitely look at. So, from the pharma space Aurobindo, from the IT space, Infosys. The two main picks that I would look at. The rest of them maybe a play based upon whatever results flow would come," he said.